Daniel Gilbert reports:
Regeneron Pharmaceuticals said Monday it will acquire 23andMe’s DNA testing business and most of its assets out of bankruptcy and pledged to continue offering the popular consumer service and adopt its privacy practices to safeguard customer data.
The drugmaker said it will deploy the company’s trove of DNA to enhance its work developing medicine, while maintaining the direct-to-consumer tests that have been used by millions to discover their ancestry and genetic risks and have turned the company into a household name. Regeneron said it was prepared to explain how it will use and protect the data to an independent, court-appointed customer privacy ombudsman.
Read more at The Washington Post.